Brain Cancer Canada Awards $68,000 Research Grant for Clinical Trial of Anti-Cancer Vaccine Targeting DIPG, the Most Aggressive Pediatric Brain Cancer
The project, "Biological Correlative Studies to Improve Current Outcomes of Diffuse Intrinsic Pontine Glioma (DIPG) and High-Risk Brain Tumours with a Neoantigen-Based Anti-Cancer Vaccine in Clinical Trial," focuses on advancing a novel immunotherapy approach for some of the most aggressive childhood brain cancers.
DIPG is a devastating pediatric brain tumour, with fewer than 10% of children surviving two years post-diagnosis. As DIPG progresses, it severely impacts essential brain functions, making it increasingly difficult for children to see, walk, and even breathe.
Current treatment options, including radiation therapy and chemotherapy, offer only temporary or limited benefit, and survival rates have remained largely unchanged for decades, despite broader advances in cancer research.
In response to this urgent need, Dr. Narendran and Dr. Sipila's team are investigating a new anti-cancer vaccine designed to train a patient's immune system to recognize and eliminate tumour cells. Their research aims to validate the safety, activity, and potential clinical applications of this neoantigen-based immunotherapy. By providing critical biological insights into the vaccine's effectiveness, the project seeks to accelerate the development of promising new treatment options for children affected by DIPG and other high-risk brain tumours.
Dr. Narendran explains, 'Every advancement in DIPG research brings renewed hope for the entire brain cancer community. By discovering new and effective treatments, we aim to prove that even the toughest human challenges can be overcome through compassion, collaboration, and innovation. The progress we make today paves the way for tomorrow's cures, where no child's future is cut short by a brain cancer.'
This groundbreaking work represents an important step toward improving survival outcomes and offering renewed hope to families impacted by these devastating diagnoses.
Brain Cancer Canada acknowledges the tremendous contributions of grassroots fundraisers including Trinity's Army, the $9 Challenge, and Dr. Surya's 8th Charity Raffle that have made this award possible.
Immensely grateful for the support, Dr. Narendran explains the critical need for funding, 'Philanthropic organizations such as the Brain Cancer Canada give true hope for children fighting brain cancer, granting the crucial support needed to advance translational research and the preparation of innovative treatment protocols for the future. By funding collaborative efforts and high-risk, high-reward projects, your giving ensures that scientists and physicians continue to work to discover safer, more effective novel treatments for our patients.'
In recognition of DIPG Day, Brain Cancer Canada is proud to have The Peace Bridge connecting Canada and the U.S., Cabot Tower on Signal Hill in St. John's, NL, and the CN Tower Toronto, ON, illuminated in yellow. The lighting serves as a powerful symbol of awareness and solidarity in the fight against DIPG.
This announcement is part of a series of six grants announced during Brain Cancer Awareness Month. Brain Cancer Canada remains committed to driving forward innovative solutions and pursuing hope for those affected by brain cancer by investing in critically needed research.
About Brain Cancer CanadaBrain Cancer Canada is a national charity dedicated to improving the lives of those affected by primary malignant brain tumours by funding research, advocating for effective treatment options, and investing in neurosurgical technologies. Since 2015, Brain Cancer Canada has directed more than 2.4 million dollars to brain cancer research, to 25 projects at nine institutions, research centres, and hospitals across Canada.
More Information
For more detail about this and other research initiatives supported by Brain Cancer Canada, please visit www.braincancercanada.ca
Media Contact:angela@braincancercanada.ca1-855-375-1381
Hashtags
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Associated Press
21 minutes ago
- Associated Press
I-Mab Presents Positive Givastomig Phase 1b Dose Escalation Data in Combination with Immunochemotherapy in Patients with 1L Gastric Cancers at ESMO GI 2025
Data show confirmed ORR of 83% (10/12) at doses selected for ongoing expansion study Median follow-up of 9.0 months as of the updated data cutoff Responses observed in patients with low PD-L1 and/or CLDN18.2 expression Company to host investor event on Tuesday, July 8th ROCKVILLE, Md., July 02, 2025 (GLOBE NEWSWIRE) -- I-Mab (NASDAQ: IMAB) (the Company), a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer, today announced the presentation of positive Phase 1b combination data for givastomig, in combination with nivolumab and mFOLFOX6, at the European Society for Medical Oncology Gastrointestinal Cancers Congress 2025 (ESMO GI 2025) in Barcelona (abstract #388MO) . Givastomig is a bispecific antibody targeting Claudin 18.2 and 4-1BB. I-Mab plans to host a virtual investor event on Tuesday, July 8th (register here ) to review these data. The Phase 1b data (NCT04900818) show a confirmed objective response rate (ORR) of 71% across all doses (12/17), and 83% (10/12) at doses selected for the ongoing dose expansion study (8 mg/kg and 12 mg/kg). Responses occurred in tumors with low levels of PD-L1 expression and/or Claudin 18.2 (CLDN18.2) expression, with favorable overall tolerability. There were no Grade 3 or greater events for nausea and vomiting, and only one Grade 3 TRAE for increased liver enzymes. The data are based on the results of the dose escalation part of a Phase 1b study evaluating the givastomig combination as first line therapy (1L) in patients with Claudin 18.2-positive gastric cancers (≥1+ IHC staining intensity in ≥1% of tumor cells). The primary endpoint is safety. The study enrolled only patients in the U.S. 'The positive Phase 1b combination data presented at ESMO GI bolster our confidence in givastomig's potential to be a best-in-class Claudin 18.2 directed therapy. Givastomig has been well tolerated when combined with immuno-oncology and chemotherapy, has shown a high objective response rate, with rapid onset and durable responses that have deepened over time, supported by consistent pharmacokinetic data and soluble 4-1BB induction,' said Phillip Dennis, MD, PhD, Chief Medical Officer of I-Mab. 'In addition, we are optimistic about the results from the 8 mg/kg and 12 mg/kg doses. These doses showed an ORR of 83%, with consistent responses across PD-L1 and Claudin 18.2 expression levels, and a favorable overall safety profile. These data further our conviction in the ongoing Phase 1b dose expansion study. We believe givastomig has broad potential in a number of gastric cancer settings and look forward to continued advancement of the program.' 'I am encouraged by the response rates, as well as the deepening of responses over time, demonstrated by the givastomig combination regimen in the Phase 1b dose escalation study that we presented today at ESMO GI. Despite approved therapies, targeted treatment options for gastric cancers continue to be limited. While the data are early, givastomig combination therapy demonstrates a high response rate across Claudin 18.2 and PD-L1 expression levels,' said Samuel J Klempner, MD, Associate Professor of Medicine at Massachusetts General Hospital. 'In addition, I have been pleased to observe that givastomig has a favorable overall tolerability profile with a low level of gastrointestinal side effects -- especially important for patients with gastric cancer. I look forward to participating in the ongoing givastomig clinical development program, and hope we may be able to expand the population of patients who may benefit from Claudin 18.2 directed agents.' Virtual Investor Event: Register ( here ) for the Post-ESMO GI 2025 Investor Event to be held on Tuesday, July 8th at 2:00 PM EDT. A replay of the webinar will be accessible on the Events page of the I-Mab website for 90 days. Fireside Chat Event with Lucid Capital Markets to Recap the Presentation: Tune in ( here ) for a fireside chat sponsored by Christopher Liu, PharmD, Managing Director at Lucid Capital Markets that will be accessible today at 2:00pm EDT on the Events page of the I-Mab website. A replay of the fireside chat will be available for 90 days. ESMO GI Presentation Details: A full copy of the ESMO GI presentation is available on the Publications and Presentations page of the I-Mab website here. Givastomig Phase 1b Dose Escalation Data Summary in 1L Gastric Cancers Patient Characteristics: Efficacy Results: Durability: Safety: About Givastomig Givastomig (TJ033721 / ABL111) is a bispecific antibody targeting Claudin 18.2 (CLDN18.2)-positive tumor cells. It conditionally activates T cells through the 4-1BB signaling pathway in the tumor microenvironment where CLDN18.2 is expressed. Givastomig is being developed for first line (1L) metastatic gastric cancers, with further potential in other solid tumors. In Phase 1 trials, givastomig has shown promising anti-tumor activity attributable to a potential synergistic effect of proximal interaction between CLDN18.2 on tumor cells and 4-1BB on T cells in the tumor microenvironment, while minimizing toxicities commonly seen with other 4-1BB agents. An ongoing Phase 1b study is evaluating givastomig for the treatment of gastric cancer in the 1L setting in combination with standard of care, nivolumab (an anti-PD-1 checkpoint inhibitor) plus chemotherapy, in dose escalation and dose expansion cohorts. Dose escalation is complete, and enrollment in the first dose expansion cohort (n=20) finished ahead of schedule. Enrollment continues to progress ahead of schedule in the second dose expansion cohort (n=20). The study builds on positive Phase 1 monotherapy data. Givastomig is being jointly developed through a global partnership with ABL Bio, in which I-Mab is the lead party and shares worldwide rights, excluding Greater China and South Korea, equally with ABL Bio. About I-Mab I-Mab (NASDAQ: IMAB) is a U.S.-based, global biotech company, focused on the development of precision immuno-oncology agents for the treatment of cancer. The Company's differentiated pipeline is led by givastomig, a potential best-in-class, bispecific antibody (Claudin 18.2 x 4-1BB) designed to treat Claudin 18.2-positive gastric cancers. Givastomig conditionally activates T cells via the 4-1BB signaling pathway in the tumor microenvironment where Claudin 18.2 is expressed. Givastomig is being developed for first-line metastatic gastric cancers, with additional potential in other solid tumors. In Phase 1 trials, givastomig was observed to maintain strong tumor-binding and anti-tumor activity, attributable to a potential synergistic effect of proximal interaction with Claudin 18.2 and 4-1BB, while minimizing toxicities commonly seen with other 4-1BB agents. For more information, please visit and follow us on LinkedIn and X. I-Mab Forward Looking Statements This announcement contains forward-looking statements. These statements are made under the 'safe harbor' provisions of the U.S. Private Securities Litigation Reform Act of 1995. These forward-looking statements can be identified by terminology such as 'will', 'expects', 'believes', 'designed to', 'anticipates', 'future', 'intends', 'plans', 'potential', 'estimates', 'confident', and similar terms or the negative thereof. I-Mab may also make written or oral forward-looking statements in its periodic reports to the U.S. Securities and Exchange Commission (the SEC), in its annual report to shareholders, in press releases and other written materials and in oral statements made by its officers, directors or employees to third parties. Statements that are not historical facts, including statements about I-Mab's beliefs and expectations, are forward-looking statements. Forward-looking statements in this press release include, without limitation, statements regarding: the Company's pipeline and clinical development of I-Mab's drug candidates, including givastomig; the projected advancement of the Company's portfolio and anticipated milestones and related timing; the Company's expectations regarding the impact of data from ongoing and future clinical trials; the timing and progress of studies and trials (including with respect to patient enrollment); the potential benefits of givastomig; and the availability of data and information from ongoing studies and trials. Forward-looking statements involve inherent risks and uncertainties that may cause actual results to differ materially from those contained in these forward-looking statements, including but not limited to the following: I-Mab's ability to demonstrate the safety and efficacy of its drug candidates; the clinical results for its drug candidates, which may or may not support further development or New Drug Application/Biologics License Application (NDA/BLA) approval; the content and timing of decisions made by the relevant regulatory authorities regarding regulatory approval of I-Mab's drug candidates; I-Mab's ability to achieve commercial success for its drug candidates, if approved; I-Mab's ability to obtain and maintain protection of intellectual property for its technology and drugs; I-Mab's reliance on third parties to conduct drug development, manufacturing and other services; and I-Mab's limited operating history and I-Mab's ability to obtain additional funding for operations and to complete the development and commercialization of its drug candidates, as well as those risks more fully discussed in the 'Risk Factors' section in I-Mab's annual report on Form 20-F filed with the SEC on April 3, 2025, as well as the discussions of potential risks, uncertainties, and other important factors in I-Mab's subsequent filings with the SEC. All forward-looking statements are based on information currently available to I-Mab. I-Mab undertakes no obligation to publicly update or revise any forward-looking statements, whether as a result of new information, future events, or otherwise, except as may be required by law. I-Mab Investor & Media Contacts PJ Kelleher LifeSci Advisors +1-617-430-7579 [email protected] [email protected]
Yahoo
20 hours ago
- Yahoo
LENSAR Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)
ORLANDO, Fla., July 01, 2025 (GLOBE NEWSWIRE) -- LENSAR, Inc. (Nasdaq: LNSR) ('LENSAR' or the 'Company') today announced that a majority of the independent members of LENSAR's board of directors granted three newly-hired non-executive employees an aggregate of 660 restricted stock units ('RSUs'). The RSUs were granted as of July 1, 2025, as inducement for each such employee commencing employment with the Company. The RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4). Each RSU represents a contingent right to receive one share of the Company's common stock. The RSUs vest in four substantially equal installments on each anniversary of the grant date, subject to the new employee's continued service with the Company through the applicable vesting date. The RSUs are subject to the terms and conditions of LENSAR's 2024 Employment Inducement Incentive Award Plan and a restricted stock unit agreement covering the grant. About LENSAR LENSAR is a commercial-stage medical device company focused on designing, developing, and marketing advanced systems for the treatment of cataracts and the management of astigmatism as an integral aspect of the procedure. LENSAR has developed its ALLY Robotic Cataract Laser System™ as a compact, highly ergonomic system utilizing an extremely fast dual-modality laser and integrating AI into proprietary imaging and software. ALLY is designed to transform premium cataract surgery by utilizing LENSAR's advanced robotic technologies with the ability to perform the entire procedure in a sterile operating room or in-office surgical suite, delivering operational efficiencies and reduced overhead. ALLY includes LENSAR's proprietary Streamline® software technology, designed to guide surgeons to achieve better outcomes. Contacts: Lee Roth / Cameron Radinovic Thomas R. Staab, II, CFO Burns McClellan for LENSAR lroth@ / cradinovic@
Yahoo
21 hours ago
- Yahoo
Fred Meyer and Washington State Collaborate to Provide Free Locking Bags to Prevent Opioid Misuse
Locking Bag Pharmacy conversation Olympia, Washington, July 01, 2025 (GLOBE NEWSWIRE) -- Customers at Fred Meyer's 60 pharmacies in Washington now have access to free locking bags to more safely store their opioid prescriptions. The Washington State Health Care Authority (HCA) is collaborating with the retailer to provide the bags as part of an ongoing effort to help prevent opioid misuse and overdose deaths in Washington's communities. Fred Meyer is the first major pharmacy chain to participate in HCA's Lock Up Your Meds safe storage program. The safe storage program supplies participating Washington pharmacies with free medication locking devices to distribute to patients with opioid prescriptions. Among the only of its kind in the nation, the program is part of the statewide Starts with One campaign to prevent opioid overdoses by increasing the safe use, storage, and disposal of opioid prescriptions. "As part of our commitment to helping people live healthier lives, we're proud to participate in this program and provide free locking bags to patients with opioid prescriptions—empowering safer communities through compassionate care and responsible pharmacy practice," said Kayla Hensley, division health leader at Fred Meyer. In Washington, approximately 82% of overdose deaths involve opioids (2023 overdose data). Nearly half of people misusing pain relievers, including prescription opioids, get them from a friend or family member. Simple steps like locking up prescriptions can help prevent both accidental and intentional misuse and potential overdose. Yet, according to a study conducted by HCA, only 44% of Washingtonians surveyed lock up their prescription medication. Providing people with a way to lock up their medications is just the first step toward changing this behavior. When a customer is given a locking bag through the Lock Up Your Meds program, the pharmacist asks them to make a pledge to lock up their opioid prescriptions. This aspect of the program is based on the research-backed idea that when someone makes a personal commitment—or a pledge—to take a specific action, they are significantly more likely to follow through. Fred Meyer has distributed a total of 713 bags, held 1,000 conversations about the importance of medication safe storage, and secured 485 pledges since it was introduced to its stores in May. 'Pharmacies play a crucial role in keeping our communities safe and informed,' said Dr. Charissa Fotinos, State Medicaid and Behavioral Health Medical Director. "We are grateful for this new relationship with Fred Meyer and for their commitment to educating residents about preventing opioid misuse and for promoting responsible medication use at their stores across Washington.' Approximately 10-17 independent pharmacies have participated each year in the four-month annual program since it started in 2020. Since its inception, there have been a total of 1,827 locking devices distributed, 3,435 patient conversations about opioid safe storage, and 1,914 pledges to lock up medications. 'This exciting relationship with Fred Meyer allows us to meaningfully expand this important evidence-based program, creating new opportunities to reach communities in all corners of Washington with life-saving opioid misuse prevention tools that are critical to reducing overdose deaths in our state,' Fotinos said. According to evaluation data, the program is successfully driving behavior change. In 2023, 95% of participating patients said that the information and resources provided through the Lock Up Your Meds program had a direct impact on how they store their medication at home. The program is funded in part by State Opioid Response (SOR) funds, which are federal grants administered by the Substance Abuse and Mental Health Services Administration to help states combat the opioid crisis. Learn more about the Lock Up Your Meds and Starts with One campaign. Contacts: HCA media relationsHCAMediaRelations@ Tiffany SandersCorporate Affairs Manager, QFC & Fred Meyer Divisions of Esther BrownLock Up Your Meds Program Managerestherb@ Contact Info Annie Groomannieg@ 509-280-8257 Attachments Locking Bag Pharmacy conversationSign in to access your portfolio
